Skip to main
CDLX
CDLX logo

Cardlytics (CDLX) Stock Forecast & Price Target

Cardlytics (CDLX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 33%
Sell 17%
Strong Sell 0%

Bulls say

Cardlytics Inc demonstrates a positive outlook due to anticipated improvements in fundamentals expected to manifest in the first quarter and continue throughout the year, driven by enhanced execution, contributions from new advertisers, and the successful launch of the American Express partnership. The company's fourth-quarter results exceeded expectations, marked by strong engagement with new advertisers and solid performance in the UK, indicating effective cost discipline and operational improvement. Additionally, the favorable balance sheet provides confidence in Cardlytics's ability to execute its turnaround strategy, suggesting potential for growth and margin enhancements moving into 2025 and beyond.

Bears say

Cardlytics Inc. faces a concerning outlook with projected revenue declines and significant challenges in achieving self-sustained growth, as indicated by anticipated billings of $91.5 million to $94.5 million in the first quarter, representing a year-over-year decrease of 10-13%. The company's fourth-quarter billings declined by 11.9% year-over-year, and expected revenue for the upcoming quarter is forecasted to drop by 11-16%, highlighting a persistent downward trend. Furthermore, the ongoing transition in business model alongside increased consumer redemptions is negatively impacting GAAP revenue, adjusted contribution dollars, EBITDA, and cash flow, contributing to a bearish financial perspective for the company.

Cardlytics (CDLX) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 33% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardlytics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardlytics (CDLX) Forecast

Analysts have given Cardlytics (CDLX) a Buy based on their latest research and market trends.

According to 12 analysts, Cardlytics (CDLX) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardlytics (CDLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.